Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9773 Phase IIb trial in severe sepsis or septic shock
2009-015168-32Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD9773 in sepsis and septic shock (3 arms), sponsored by AstraZeneca. Primary endpoint: Ventilator-free days. Started May 2010; status: completed.
02
Drugs
AZD9773
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2009-015168-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015168-32.